Please Note: This trial is no longer enrolling new participants
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects with Selected Relapsed/Refractory B cell Malignancies
| Protocol No. | CTO-P-CD19CD20-ALLO1-001 | Scope | National |
|---|---|---|---|
| Principal Investigator | Huda Salman | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase I |
